NovaBay stock: buy or sell?

NBY stock price: $1.68 -4.55% At close on June 26th, 2019

Updated on:
June 26th, 2019

3

NovaBay Pharmaceuticals shares plunged -4.55% to $1.68 today. On Jun/18 NBY skyrocketed an exceptional 10.71%. Wednesday was the 4th red session in a row, sliding in full a -18.27%. On June 24th NBY collapsed a dreadful -5.49%.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States.

Should I buy NovaBay stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, NovaBay Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean NBY will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is NovaBay Pharmaceuticals stock a buy?

Banks and financial institutions post stock ratings everyday. Unfortunately, we couldn't detect any rating for NBY stock for the last 30 days.

NovaBay stock analysis

Daily outlook

NovaBay plunged a chilling -4.55% and closed at $1.68.

Shares of NovaBay plunged a chilling -4.55% and closed at $1.68. Since price and SMA200d lines crossed up on June/10, NBY climbed $1.36 (425.00%).

NBY stock chart (daily)

Weekly outlook

After boosting an exceptional 13.54% in a week last week, NovaBay Pharmaceuticals closed this week at $1.68 and plunged a bloodcurdling -12.50%.

Since price and SMA40w lines crossed up by mid June, NBY climbed $1.36 (425.00%).

NBY stock chart (weekly)

NovaBay stock price history

NovaBay IPO was on January 2nd, 2018 at $3.90 per share1. Since then, NBY stock lost a -56.90%, with a yearly average of -56.90%.

1: Adjusted price after possible price splits or reverse-splits.

NovaBay stock historical price chart

NBY stock reached 52-week highs on Jun/11 at $4.04, and all-time highs 2018-01-02 with a price of 4.2.

NovaBay stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price forecast for NovaBay Pharmaceuticals stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

NovaBay failed experts on March when it published an Earnings per Share (EPS) of $-0.09 when the market consensus was $-0.14.
NBY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.26n/a
2017-Q2-n/a-0.11n/a
2017-Q32017-11-10-0.09-0.16n/a
2017-Q42018-03-20-0.050.02n/a
2018-Q12018-05-10-0.07-0.14n/a
2018-Q22018-08-07-0.12-0.15n/a
2018-Q32018-11-14-0.09-0.11n/a
2018-Q42019-03-28-0.14-0.09n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual sales report draw a spooky slide of -31.39% to $12.51 M USD. Similarly, its income margin (compared to revenues) plunged to -52.33%, that is $-6.55 million.

NBY annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$3.48 M-$-16.04 M-460.9%-
2014$1.05 M-69.71%$-15.19 M-1441.6%-5.27%
2015$4.38 M315.65%$-18.97 M-433.1%24.87%
2016$12 M171.56%$-13.15 M-110.5%-30.69%
2017$18 M53.23%$-7.40 M-40.6%-43.71%
2018$13 M-31.39%$-6.55 M-52.3%-11.59%

Quarterly financial results

NovaBay Pharmaceuticals reported $3.63 million in sales for 2018-Q4, a 15.37% up compared to previous quarter. Reported quarter earnings marked $-1.27 million with a profit margin of -34.98%. Profit margin boosted a 13.97% compared to previous quarter when profit margin was -48.95%. When comparing revenues to same quarter last year, NovaBay sales marked a chilling correction and plunged a -42.61%. Looking back to recent quarterly results, NovaBay posted 2 negative quarters in a row.
NBY quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$4 M-$-4.01 M-108.4%-
2017-Q2$4 M11.35%$-1.74 M-42.2%-56.61%
2017-Q3$4 M-0.70%$-2.45 M-59.8%40.63%
2017-Q4$6 M54.39%$0.79 M12.6%-132.41%
2018-Q1$3 M-53.34%$-2.15 M-73.0%-371.12%
2018-Q2$3 M-5.19%$-1.59 M-56.9%-26.09%
2018-Q3$3 M12.46%$-1.54 M-48.9%-3.21%
2018-Q4$4 M15.37%$-1.27 M-35.0%-17.56%

NovaBay ownership

When you are planning to invest in shares of a company, it's worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For NovaBay Pharmaceuticals, 25.87% of all outstanding shares are owned by its staff.

In case of NovaBay stock, 4.11% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NBY stock account 0.00%, no big difference from last month.

For a better understanding, the following table shows ownership data compared to other related stocks:

NBYJNJNNVCSIGASNOA
Market cap$31.9 M$377.3 B$19.2 M$436.3 M$94.6 M
Total shares19.0 M2,660.0 M76.7 M80.9 M12.0 M
Float shares7.1 M2,650.0 M54.5 M49.7 M11.7 M
  - Institutional holdings (%)4.1%69.2%5.0%30.2%14.5%
  - Insider holdings (%)25.9%0.1%28.1%33.0%2.0%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

NovaBay summary

Wednesday, June 26th, 2019
Open$1.72
Close$1.68
Day range$1.66 - $1.76
Previous close$1.76
Session gain-4.55%
Average true range$0.65
50d mov avg$0.99
100d mov avg$1.19
200d mov avg$1.27
Daily patternlt01a
Weekly pattern

NovaBay performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We chose , NanoViricides, SIGA Technologies, Sonoma Pharmaceuticals and Tetraphase Pharmaceuticals as the bechmarking frame for NovaBay Pharmaceuticals stock.
Stock3m6m12m
NBYNovaBay Pharmaceu...40.00%104.88%-32.80%
JNJ2.17%12.96%20.03%
NNVCNanoViricides-7.41%13.64%-43.18%
SIGASIGA Technologies-10.32%-27.26%-9.26%
SNOASonoma Pharmaceut...-6.62%29.08%-64.61%
TTPHTetraphase Pharma...-64.93%-55.24%-86.83%

NovaBay competitors

We selected a few stocks to conform a list of NovaBay Pharmaceuticals competitors to examine if you are interested in investing in NBY: